%C United States
%N 3
%L discovery10043575
%X OBJECTIVE: Information about Rivaroxaban plasma levels (RivLev) may guide treatment decisions in patients with acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH) taking rivaroxaban. METHODS: In a multicenter registry-based study (Novel-Oral-Anticoagulants-In-Stroke-Patients collaboration;NOACISP;ClinicalTrials.gov:NCT02353585) of patients with stroke while taking rivaroxaban, we compared RivLev in patients with AIS and ICH. We determined how many AIS-patients had RivLev≤100ng/ml, indicating possible eligibility for thrombolysis and how many ICH-patients had RivLev≥75ng/ml, possibly eligible for the use of specific reversal agents. We explored factors associated with RivLev (Spearman correlation; regression models) and studied the sensitivity and specificity of INR-thresholds to substitute RivLevs using cross tables and ROC curves. RESULTS: Among 241 patients (median age 80 years[IQR73-84], median time-from-onset-to-admission 2 hours[IQR1-4.5hours], median RivLev 89ng/ml[31-194]), 190 had AIS and 51 had ICH. RivLev were similar in AIS-patients (82ng/ml[IQR30-202] and ICH-patients (102ng/ml[IQR 51-165]; p=0.24). Trough RivLev(≤137ng/ml) occurred in 126/190 (66.3%) AIS- and 34/51 (66.7%) ICH-patients. Among AIS-patients, 108/190 (56.8%) had RivLev≤100ng/ml. In ICH-patients 33/51(64.7%) had RivLev≥75ng/ml. RivLev were associated with rivaroxaban dosage, inversely with renal function and time-since-last-intake (each p<.05). INR≤1.0 had a specificity of 98.9% and a sensitivity of 25.7% to predict RivLev≤100ng/ml. INR≥1.4 had a sensitivity of 59.3% and specificity of 90.1% to predict RivLev≥75ng/ml. INTERPRETATION: RivLev did not differ between patients with AIS and ICH. Half of the patients with AIS under Rivaroxaban had RivLev low enough to consider thrombolysis. In ICH-patients, 2/3 had RivLev high enough to meet the eligibility for the use of a specific reversal agent. INR-thresholds perform poor to inform treatment decisions in individual patients. This article is protected by copyright. All rights reserved.
%T Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage
%A DJ Seiffge
%A G Kägi
%A P Michel
%A U Fischer
%A Y Béjot
%A S Wegener
%A M Zedde
%A G Turc
%A C Cordonnier
%A PS Sandor
%A G Rodier
%A A Zini
%A M Cappellari
%A S Schädelin
%A AA Polymeris
%A D Werring
%A S Thilemann
%A I Maestrini
%A E Berge
%A C Traenka
%A J Vehoff
%A GM De Marchis
%A M Kapauer
%A N Peters
%A G Sirimarco
%A LH Bonati
%A M Arnold
%A PA Lyrer
%A E De Maistre
%A A Luft
%A DA Tsakiris
%A ST Engelter
%A . NOACISP study group
%J Annals of Neurology
%P 451-459
%O © 2018 American Neurological Association. This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
%D 2018
%V 83